Serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors and other antidepressants and persistent sexual dysfunction - An EudraVigilance analysis

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/39113
• EU PAS number:
  EUPAS39112
• Study ID:
  39113
• Official title and acronym:
  Serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors and other antidepressants and persistent sexual dysfunction - An EudraVigilance analysis
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This study was conducted to describe the case reports of persistent sexual dysfunctions to Serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors and other antidepressants.
• Study status:
  Finalised

Research institutions and networks

Institutions

European Medicines Agency (EMA)

Study timelines

Date when funding contract was signed

Planned: 04/12/2018

Actual: 07/12/2018

Study start date

Planned: 07/12/2018

Actual: 07/12/2018

Date of final study report

Planned: 13/02/2019

Actual: 26/02/2019

Sources of funding

EMA

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable